Belite Bio, Inc (BLTE) News
Filter BLTE News Items
BLTE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BLTE News From Around the Web
Below are the latest news stories about BELITE BIO INC that investors may wish to consider to help them evaluate BLTE as an investment opportunity.
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceSAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will be participating at the Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7, 2023, at the New York Athletic Club in New York City. To schedule a one-on-one me |
Belite Bio to Participate in the BTIG Ophthalmology DaySAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that management will participate in a fireside chat at the BTIG Ophthalmology Day on Monday, November 27, 2023, at 3:00 p.m. ET. The Belite management team will be participating in one-on-one meetings at the event. Investor |
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial ResultsComparison of the 24-month DDAF lesion growth between Tinlarebant-treated subjects and ProgStar participants Comparison of the 24-month DDAF lesion growth between Tinlarebant-treated subjects and ProgStar participants Comparison between Tinlarebant-treated subjects and ProgStar participants Comparison between Tinlarebant-treated subjects and ProgStar participants Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 104 subjects enr |
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online ViewingCompany Executives Share Vision and Answer Questions at VirtualInvestorConferences.comNEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Deutsche Bank Depositary Receipts Virtual Investor Conference (“dbVIC”) held on November 8th and 9th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3SyFOaq The company presentations will be available 24/7 for 90 days. Nove |
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial ResultsSAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results for the third quarter ended September 30, 2023, and provide a general business update. Webcast I |
Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event Growth of Incident DDAF Retinal Lesions Phase 2 Trial Results SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Belite Bio’s Chief Scientific Off |
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual MeetingComparison of the 24-month DDAF lesion growth between Tinlarebant-treated subjects and ProgStar participants Comparison of the 24-month DDAF lesion growth between Tinlarebant-treated subjects and ProgStar participants Comparison between Tinlarebant-treated subjects and ProgStar participants Comparison between Tinlarebant-treated subjects and ProgStar participants Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with |
International companies to host live webcasts at Deutsche Bank’s Depositary ReceiptsVirtual Investor Conference on November 8th and 9th, 2023NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday, November 9, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in Australia, China, France, Germany, Greece, Hong Kong, Netherla |
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday, November 9, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in Australia, China, France, Germany, Greece, Hong Kong, Netherlands, Philippines and Taiwan will respond to questions dur |
Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual MeetingTwo-year data from the two-year Phase 1b/2 trial of Tinlarebant (LBS-008) in adolescent Stargardt Disease (STGD1) to be presentedA two-year global Phase 3 trial in adolescent STGD1 (the “DRAGON” study) and a two-year global Phase 3 trial in Geographic Atrophy (GA) patients (the “PHOENIX” study) are on-goingTinlarebant has been granted Fast Track and Rare Pediatric Disease Designations in the U.S. and Orphan Drug Designation in both the U.S. and Europe for STGD1, for which there are no FDA approv |